Tuesday April 23, 2019

Study Shows That Drug to treat bleeding may benefit some stroke patients

A drug, currently used to treat blood loss from major trauma and bleeding after childbirth, may benefit patients with stroke caused by bleeding in the brain -- intracerebral haemorrhage, a clinical trial suggests.

0
//
Children and adults treated with oral antibiotics may have a higher risk of developing kidney stones, according to a new study.
Antibiotics, Pixabay

A drug, currently used to treat blood loss from major trauma and bleeding after childbirth, may benefit patients with stroke caused by bleeding in the brain — intracerebral haemorrhage, a clinical trial suggests.

Intracerebral haemorrhage occurs when a diseased blood vessel within the brain bursts, allowing blood to leak inside the brain.

The study, published in the journal The Lancet, found that giving tranexamic acid (TXA) to people who had experienced intracerebral haemorrhage reduced the number of deaths in the early days following the stroke.

It also showed that both the amount of bleeding in the brain and the number of associated serious complications were lower in the patients who had received the TXA treatment, the researchers from the University of Nottingham said.

 

For the study, researchers recruited more than 2,000 patients who were diagnosed as having had bleeding in the brain -- confirmed by CT scan -- from 124 hospitals in 12 countries between 2013 and 2017.
representational image, Pixabay

Patients who received TXA treatment experienced lower associated serious complications — such as pneumonia and brain swelling — as compared to those who had not, the researchers added.

 

However, the trial found no difference in the number of people who were left disabled or had died at three months after their stroke — the study’s primary outcome.

“While we failed to show significant benefits three months after stroke, the reduction in early deaths, amount of bleeding on the brain and serious complications are signs that this drug may be of benefit in the future,” said co-author Nikola Sprigg, Professor at the University of Nottingham.

For the study, researchers recruited more than 2,000 patients who were diagnosed as having had bleeding in the brain — confirmed by CT scan — from 124 hospitals in 12 countries between 2013 and 2017.

They were randomly sorted into two patient groups — one received TXA within eight hours of their stroke and another was given a saline placebo.

Also Read: Study Shows That 3 Cups of Coffee or Tea Daily May Cut Risk of Stroke

CT scans of the patients’ brains were performed 24 hours after their stroke and their progress was monitored and measured at day two and day seven after their stroke. The final follow up was performed at 90 days.

The researchers have highlighted the need for further studies to find out whether giving an earlier dose of TXA might be beneficial for patients. (IANS)

Next Story

Parkinson Treatment Possible Through A Blood Pressure Drug

Felodipine was effective at reducing the build-up of "aggregates" in mice with the Huntington's and Parkinson's disease mutations and in the zebrafish dementia model. 

0
blood pressure
"This is the first time that we're aware of that a study has shown that an approved drug can slow the build-up of harmful proteins in the brains of mice using doses aiming to mimic the concentrations of the drug seen in humans," said Professor Rubinsztein. Pixabay

Felodipine, a prescribed drug to treat high blood pressure, has shown promise against Parkinson’s, Huntington’s and forms of dementia in studies carried out in mice and zebrafish at the University of Cambridge.

In a study published in the journal Nature Communications, scientists have shown in mice that felodipine may be a candidate for re-purposing.

A common feature of neurodegenerative diseases is the build-up of misfolded proteins.

drug

The hypertension drug was able to slow down progression of these potentially devastating conditions and “so we believe it should be trialled in patients,” he added. VOA

These proteins, such as huntingtin in Huntington’s disease and tau in some dementias, form “aggregates” that can cause irreversible damage to nerve cells in the brain.

A team led by Professor David Rubinsztein used mice that had been genetically modified to express mutations that cause Huntington’s disease or a form of Parkinson’s disease, and zebrafish that model a form of dementia.

Felodipine was effective at reducing the build-up of “aggregates” in mice with the Huntington’s and Parkinson’s disease mutations and in the zebrafish dementia model.

The treated animals also showed fewer signs of the diseases.

“This is the first time that we’re aware of that a study has shown that an approved drug can slow the build-up of harmful proteins in the brains of mice using doses aiming to mimic the concentrations of the drug seen in humans,” said Professor Rubinsztein.

The hypertension drug was able to slow down progression of these potentially devastating conditions and “so we believe it should be trialled in patients,” he added.

brain

These proteins, such as huntingtin in Huntington’s disease and tau in some dementias, form “aggregates” that can cause irreversible damage to nerve cells in the brain.
Pixabay

In healthy individuals, the body uses a mechanism to prevent the build-up of such toxic materials.

Also Read: Facebook Reveals Millions of Instagram Passwords Stored on Servers

This mechanism is known as autophagy, or ‘self-eating’, and involves cells eating and breaking down the materials.

“This is only the first stage, though. The drug will need to be tested in patients to see if it has the same effects in humans as it does in mice. We need to be cautious, but I would like to say we can be cautiously optimistic,” said Professor Rubinsztein. (IANS)